Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00486317 |
Recruitment Status
:
Completed
First Posted
: June 14, 2007
Last Update Posted
: June 14, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Osteoarthritis | Drug: Oral salmon calcitonin, salmon calcitonin nasal spray | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study. |
Study Start Date : | October 2005 |

- Number of adverse events
- Changes in Urine CTX-I and CTX-II
- Changes in serum osteocalcin

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 52 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Medical history and symptoms of knee osteoarthritis
Exclusion Criteria:
- Any other disease or medication affecting the bone or cartilage.
- Any clinical signs or laboratory evidence diseases, which in the Investigator's opinion would preclude the participant from adhering to the Protocol or completing the trial.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00486317
Denmark | |
CCBR A/S | |
Ballerup, Denmark, 2750 |
Study Chair: | Bente J Riis, M.D. | Nordic Bioscience A/S |
ClinicalTrials.gov Identifier: | NCT00486317 History of Changes |
Other Study ID Numbers: |
SMC021A2110 |
First Posted: | June 14, 2007 Key Record Dates |
Last Update Posted: | June 14, 2007 |
Last Verified: | June 2007 |
Keywords provided by Nordic Bioscience A/S:
Osteoarthritis, oral salmon calcitonin, tolerability, biomarkers |
Additional relevant MeSH terms:
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Salmon calcitonin |
Calcitonin Calcitonin Gene-Related Peptide Bone Density Conservation Agents Physiological Effects of Drugs Vasodilator Agents |